ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 251 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,129,200 | -78.2% | 60,000 | -81.5% | 0.26% | -79.5% |
| Q4 2022 | $5,174,001 | -2.7% | 325,000 | 0.0% | 1.25% | +17.7% |
| Q3 2022 | $5,317,000 | +11458.7% | 325,000 | +17168.9% | 1.06% | +17566.7% |
| Q1 2022 | $46,000 | +9.5% | 1,882 | +6.6% | 0.01% | 0.0% |
| Q4 2021 | $42,000 | -99.1% | 1,765 | -99.4% | 0.01% | -98.2% |
| Q3 2021 | $4,681,000 | -8.6% | 281,765 | +34.3% | 0.33% | -20.3% |
| Q2 2021 | $5,119,000 | -66.0% | 209,866 | -64.1% | 0.41% | -18.3% |
| Q1 2021 | $15,076,000 | +403.4% | 584,308 | +943.3% | 0.51% | +284.1% |
| Q4 2020 | $2,995,000 | -53.5% | 56,008 | -64.1% | 0.13% | -71.7% |
| Q3 2020 | $6,436,000 | -46.0% | 156,008 | -36.6% | 0.47% | -50.8% |
| Q2 2020 | $11,924,000 | -27.6% | 246,008 | -36.9% | 0.95% | -23.5% |
| Q1 2020 | $16,478,000 | +175.1% | 390,000 | +178.6% | 1.24% | +27.8% |
| Q4 2019 | $5,989,000 | – | 140,000 | – | 0.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |